Amy V. Kapp

3.0k total citations · 1 hit paper
30 papers, 1.8k citations indexed

About

Amy V. Kapp is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Amy V. Kapp has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Molecular Biology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Amy V. Kapp's work include HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Amy V. Kapp is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). Amy V. Kapp collaborates with scholars based in United States, Spain and South Korea. Amy V. Kapp's co-authors include Robert Tibshirani, Steinar Aamdal, Martin Gore, Dirk Schadendorf, Brigitte Dréno, Gerhard Fierlbeck, J. Weiss, Paul Statkevich, Uwe Fraass and Simone Seiter and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Amy V. Kapp

30 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 936 citations Amy V. Kapp et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy V. Kapp United States	14	1.2k	909	438	343	195	30	1.8k
Erika von Euw United States	18	757 0.6×	893 1.0×	353 0.8×	269 0.8×	209 1.1×	30	1.6k
Lucia B. Jilaveanu United States	29	1.3k 1.1×	1.0k 1.1×	456 1.0×	826 2.4×	234 1.2×	66	2.3k
Mohammed M. Dar United States	19	820 0.7×	891 1.0×	336 0.8×	280 0.8×	184 0.9×	42	1.7k
Rosemary L. Balleine Australia	23	791 0.7×	649 0.7×	291 0.7×	187 0.5×	481 2.5×	58	2.0k
Cornelia Quadt Switzerland	25	756 0.6×	1.4k 1.6×	260 0.6×	591 1.7×	273 1.4×	53	2.2k
Michael Bockmayr Germany	21	649 0.5×	394 0.4×	294 0.7×	280 0.8×	278 1.4×	35	1.4k
Rodabe N. Amaria United States	21	1.4k 1.1×	776 0.9×	563 1.3×	286 0.8×	110 0.6×	117	1.8k
Maciej Kmieciak United States	24	971 0.8×	849 0.9×	876 2.0×	149 0.4×	225 1.2×	66	2.0k
Joan T. Garrett United States	19	1.1k 1.0×	1.2k 1.3×	223 0.5×	392 1.1×	229 1.2×	30	2.0k
Tomoko Freshwater United States	13	1.0k 0.9×	783 0.9×	226 0.5×	213 0.6×	152 0.8×	27	1.5k

Countries citing papers authored by Amy V. Kapp

Since Specialization

Citations

This map shows the geographic impact of Amy V. Kapp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy V. Kapp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy V. Kapp more than expected).

Fields of papers citing papers by Amy V. Kapp

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy V. Kapp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy V. Kapp. The network helps show where Amy V. Kapp may publish in the future.

Co-authorship network of co-authors of Amy V. Kapp

This figure shows the co-authorship network connecting the top 25 collaborators of Amy V. Kapp. A scholar is included among the top collaborators of Amy V. Kapp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy V. Kapp. Amy V. Kapp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diefenbach, Catherine, Paolo F. Caimi, Nakhle S. Saba, et al.. (2024). Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study. Blood. 144(Supplement 1). 987–987. 5 indexed citations

Rodríguez‐Abreu, Delvys, Melissa L. Johnson, Maen Hussein, et al.. (2020). Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).. Journal of Clinical Oncology. 38(15_suppl). 9503–9503. 191 indexed citations

Oliveira, Mafalda, Cristina Saura, Isabel Calvo, et al.. (2018). Abstract CT041: Primary results from FAIRLANE (NCT02301988), a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (eTNBC). Cancer Research. 78(13_Supplement). CT041–CT041. 3 indexed citations

Wongchenko, Matthew, Doron Lipson, Travis Clark, et al.. (2018). Abstract 2964: On-treatment changes in circulating tumor DNA (ctDNA) level as an early predictor of clinical outcome in the LOTUS randomized phase 2 trial of 1st-line ipatasertib (IPAT) + paclitaxel (PAC) for metastatic triple-negative breast cancer (mTNBC). Cancer Research. 78(13_Supplement). 2964–2964. 1 indexed citations

Dent, Rebecca, Sung‐Bae Kim, Seock‐Ah Im, et al.. (2017). LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 35(15_suppl). 1009–1009. 2 indexed citations

Fayette, Jérôme, Lori J. Wirth, Cristina Oprean, et al.. (2016). Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology. 6. 232–232. 84 indexed citations

Cheah, Chan Y., David Belada, Michelle A. Fanale, et al.. (2015). Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. The Lancet Haematology. 2(4). e166–e174. 36 indexed citations

Penuel, Elicia, Amy V. Kapp, Rachel Tam, et al.. (2015). Abstract 1553: Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]. Cancer Research. 75(15_Supplement). 1553–1553. 2 indexed citations

Wirth, Lori J., Pol Specenier, Amy V. Kapp, et al.. (2014). Phase 1b Study of MEHD7945A (DULIGOTUZUMAB) Plus Cisplatin/Fluorouracil or Carboplatin/Paclitaxel for First-Line Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck. 1 indexed citations

10.

Wainberg, Zev A., Wells A. Messersmith, Parvin F. Peddi, et al.. (2013). A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 12(4). 248–254. 50 indexed citations

11.

Bendell, Johanna C., Mark Kozloff, Amy V. Kapp, et al.. (2012). Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 30(15_suppl). 3543–3543. 13 indexed citations

12.

Juric, Dejan, Rodrigo Dienstmann, Wells A. Messersmith, et al.. (2012). Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors. Cancer Research. 72(8_Supplement). CT–8. 4 indexed citations

13.

Harris, Jeffrey M., Dennis A. Wong, & Amy V. Kapp. (2011). Development of the Asthma Control Composite outcome measure to predict omalizumab response. Annals of Allergy Asthma & Immunology. 107(3). 273–280.e1. 10 indexed citations

14.

Huffstutter, J. Eugene, James C. Taylor, Joy Schechtman, et al.. (2011). Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial. International Journal of Clinical Rheumatology. 6(6). 689–696. 5 indexed citations

15.

Kapp, Amy V., et al.. (2008). CHIRALITY VS. HOMFLY AND KAUFFMAN POLYNOMIALS. Journal of Knot Theory and Its Ramifications. 17(12). 1519–1524. 2 indexed citations

16.

Gratzinger, Dita, Shuchun Zhao, Robert J. Marinelli, et al.. (2007). Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes. American Journal Of Pathology. 170(4). 1362–1369. 67 indexed citations

17.

Kapp, Amy V., Stefanie S. Jeffrey, Anita Langerød, et al.. (2007). Discovery and validation of breast cancer subtypes. BMC Genomics. 8(1). 101–101. 5 indexed citations

18.

Kapp, Amy V., Stefanie S. Jeffrey, Anita Langerød, et al.. (2006). Discovery and validation of breast cancer subtypes. BMC Genomics. 7(1). 231–231. 90 indexed citations

19.

Kapp, Amy V. & Robert Tibshirani. (2006). Are clusters found in one dataset present in another dataset?. Biostatistics. 8(1). 9–31. 127 indexed citations

20.

Kapp, Amy V.. (1953). Does the Logical Truth (existx) (fx v fx) Entail that at Least One Individual Exists?. Analysis. 14(1). 2–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact